COVID-19 (Novel Coronavirus) Updates: For the latest information on the status of AAIC, policies and how to reach us, visit our COVID-19 updates page.

Scientific Sessions

 


On This Page:

Plenary Sessions

The schedule below reflects the invited program only. The complete schedule, including the submitted program, will be available closer to the conference.

Program

10:30 - 11:15 a.m.

Association Welcome


Session: PL-01-01

11:15 - 11:45 a.m.

Imaging Biomarkers and Alzheimer's Disease Prevention

Susan M. Landau, Ph.D.
Helen Wills Neuroscience Institute, University of California, Berkeley, United States
Theme: Biomarkers

Session: PL-01-02

10:30 - 11 a.m.

Proteostasis/Autophagy


Ralph A. Nixon, M.D., Ph.D.
Nathan S. Kline Institute for Psychiatric Research; NYU Langone Medical Center, United States
Theme: Basic Science and Pathogenesis

Session: PL-02-01

11 - 11:30 a.m.

Global Guidelines for Dementia Risk Reduction


Kaarin Anstey, Ph.D.
UNSW Ageing Futures Institute; NeuRA; ARC Centre of Excellence in Population Ageing Research; NHMRC Dementia Centre for Research Collaboration, Australia
Theme: Dementia Care and Psychosocial Factors and Public Health

Session: PL-02-02

10:30 - 11 a.m.

To Be Announced


Session: PL-03-01

11 - 11:30 a.m.

Epidemiology of Dementia in Diverse Populations


Lisa L. Barnes, Ph.D.
Rush Alzheimer’s Disease Center, United States
Theme: Dementia Care and Psychosocial Factors and Public Health

Session: PL-03-02

10:30 - 11 a.m.

The Two Indias


Viji Ravindranath, Ph.D.
Indian Institute of Science, India
Theme: Basic Science and Pathogenesis

Session: PL-04-01

11 - 11:30 a.m.

To Be Announced


Session: PL-04-02

10:30 - 11 a.m.

Blood Based Biomarkers


Charlotte Teunissen, Ph.D.
Amsterdam UMC, Netherlands
Theme: Biomarkers

Session: PL-05-01

11 - 11:30 a.m.

Mechanisms of Neurovascular Dysfunction and Interaction With Alzheimer's Disease Pathology


Costantino Iadecola, M.D.
Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, United States
Theme: Clinical Manifestations

Session: PL-05-02


Symposium Sessions

Sunday, July 26
  • Dementia and Cognitive Health in LGBTQ Older Adults [S1-01]
    8 – 9:30 a.m.

    Theme: Public Health | Topic: Epidemiology

PRESENTATIONS

SPEAKERS


Interventions for LGBTQ Older Adults With ADRD and Their Care Partners [S1-01-01]

Karen Fredriksen-Goldsen
University of Washington, United States


The Epidemiology of ADRD in LGBTQ Older Adults [S1-01-02]

Jason Flatt
University of California, San Francisco, United States


LGBTQ Older Adults With Cognitive Impairment: Implications for Early Diagnosis, Treatment and Care [S1-01-03]

Sue Westwood
University of York, United Kingdom


To Be Announced [S1-01-04]

To Be Announced

  • Immunity in the Aging or Diseased Brain [S1-02]
    8 - 9:30 a.m.

    Theme: Basic and Science Pathogenesis | Topic: Human Neuropathology

PRESENTATIONS

SPEAKERS


To Be Announced [S1-02-01]

To Be Announced


To Be Announced [S1-02-02]

To Be Announced


Microglia Depletion/Repopulation [S1-02-03]

Kim Green
University of California, Irvine, United States


Microglial Immune Memory [S1-02-04]

Jonas Neher
Research Institute in Tübingen, Germany


Monday, July 27
  • Ethics in Dementia [S2-01]
    8 – 9:30 a.m.

    Theme: Clinical Manifestations | Topic: Neuropsychiatry and Behavioral Neurology

PRESENTATIONS

SPEAKERS


APOE Disclosure: One Investigator of the REVEAL Study [S2-01-01]

J. Scott Roberts
University of Michigan, United States


Expectations and Effects of Biomarker-Based Dementia Risk Prediction in MCI – The PreDaDQual Project [S2-01-02]

Ayda Rostamzadeh
University Hospital of Cologne, Germany


Communication of Risk for Dementia in MCI – The ABIDE Project [S2-01-03]

Jetske van der Schaar
VU Medical Center, Netherlands


Amyloid Disclosure in Mild Cognitive Impairment [S2-01-04]

Jennifer Lingler
University of Pittsburgh, United States

  • Measuring Tau Accumulation And Progression [S2-02]
    8 - 9:30 a.m.

    Theme: Biomarkers | Topic: Biomarkers (Non-Neuroimaging)

PRESENTATIONS

SPEAKERS


Tau Progression Evidence From Tau PET Imaging [S2-02-01]

Rik Ossenkoppele
Alzheimer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands; Lund University, Sweden


To Be Announced [S2-02-02]

To Be Announced


Genetics of Tau Accumulation and Progression [S2-02-03]

Philip De Jager
Broad Institute of MIT and Harvard, United States


Interaction of Tau With Other Pathologies [S2-02-04]

Virginia Lee
University of Pennsylvania, United States


Tuesday, July 28
  • Using Technology to Assess Cognition in the Community [S3-01]
    8 – 9:30 a.m.

    Theme: Clinical Manifestations | Topic: Neuropsychology

PRESENTATIONS

SPEAKERS


Unsupervised Online Neuropsychological Testing – The Principles [S3-01-01]

Paul Maruff
The Florey Institute of Neuroscience and Mental Health, Australia


To Be Announced [S3-01-02]

To Be Announced


Technology to Enhance Social Stimulation and Reduce Problem Behaviors [S3-01-03]

Jesus Favela
CICESE Research Center, Mexico


Testing on Mobile Devices [S3-01-04]

Simon Collinson
Savonix, Singapore

  • Toward a Precision Medicine Approach in Alzheimer’s Disease [S3-02]
    8 - 9:30 a.m.

    Theme: Biomarkers | Topic: Biomarkers (Non-Neuroimaging)

PRESENTATIONS

SPEAKERS


Blood-Based Biomarkers to Predict Current and Future Brain Amyloidosis [S3-02-01]

Randall Bateman
Knight Alzheimer Disease Research Center, United States


Accurate Prediction of β-Amyloid Positivity Using Risk Models and Plasma Aβ and P-tau Analyses [S3-02-02]

Sebastian Palmqvist
Lund University, Sweden


Biomarker-Based Prognosis for People With Mild Cognitive Impairment [S3-02-03]

Ingrid Van Maurik
Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands


Organizing Mechanistic Knowledge About Neurodegenerative Diseases for the Improvement of Drug Development and Therapy [S3-02-04]

Martin Hofmann-Apitius
Fraunhofer Institute for Algorithms and Scientific Computing SCAI, Germany


Wednesday, July 29
  • Repurposing Drugs Targeting Glia and Inflammatory Mechanisms [S4-01]
    8 – 9:30 a.m.

    Theme: Drug Development | Topic: Human

PRESENTATIONS

SPEAKERS


Role of Inflammatory Cells in Neurodegeneration [S4-01-01]

Malu Tansey
Emory University, United States


Senolytic Therapies Targeting Oligodendrocyte Precursor Cells [S4-01-02]

Howard Fillit
The Alzheimer’s Drug Discovery Foundation, United States


Microglial Cells in AD: Good Guys or Bad Guys? [S4-01-03]

Knut Biber
AbbVie Deutschland GmbH & Co. KG, Germany


To Be Announced [S4-01-04]

To Be Announced


Thursday, July 30
  • Repurposing Drugs Targeting Glia and Inflammatory Mechanisms [S5-01]
    8 – 9:30 a.m.

    Theme: Drug Development | Topic: Human

PRESENTATIONS

SPEAKERS


Amyloid-Related Imaging Abnormalities (ARIA) [S5-01-01]

James Nicoll
University Hospital Southampton NHS Foundation Trust, United Kingdom


Cerebrovascular Disease [S5-01-02]

Donna Wilcock
University of Kentucky, United States


Trauma-Related Axonal Damage [S5-01-03]

Victoria Johnson
University of Pennsylvania, United States


Neuroimaging of White Matter Hyperintensities (WMH) [S5-01-04]

Joanna Wardlaw
University of Edinburgh, United Kingdom


Become an ISTAART Member

ISTAART members receive discounted registration rates and access to exclusive events at AAIC. Join today for these benefits and much more.


JOIN NOW

Join the Conversation #AAIC20

Follow

Exhibitors

Exhibitors

Sponsors

Sponsorship

> 1200px
lg
> 992px
md
> 768px
sm
< 767px
xs